Compare TH & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TH | MPLT |
|---|---|---|
| Founded | 1978 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2017 | 2025 |
| Metric | TH | MPLT |
|---|---|---|
| Price | $19.52 | $13.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $16.50 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 1.2M | 553.7K |
| Earning Date | 05-18-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $320,635,000.00 | N/A |
| Revenue This Year | $17.45 | N/A |
| Revenue Next Year | $38.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.97 | $9.10 |
| 52 Week High | $20.85 | $40.43 |
| Indicator | TH | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 39.67 |
| Support Level | $15.49 | $12.24 |
| Resistance Level | $18.83 | $20.20 |
| Average True Range (ATR) | 0.96 | 0.94 |
| MACD | 0.14 | 0.89 |
| Stochastic Oscillator | 68.81 | 74.93 |
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services, including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. The company has three reportable segments: HFS - South, which provides specialty rental and hospitality services to the natural resources and development industry; WHS, which provides construction and hospitality solutions for critical mineral and data center projects; and Government, which provides specialty rental and hospitality services under government contracts.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.